30 Day Trial

BARE BONES content is posted to these pages in real time.

Monthly compilations are available in PDF form.

Strategic Initiatives

Bone Biologics Signs Option to License Nell-1 Bone Growth Factor for Use in Osteoporosis -

Bone Biologics signed an option agreement with UCLA for an opportunity to exclusively license the use of Nell-1 bone growth factor in the treatment of osteoporosis.

Bone Biologics is presently funding the development of a Nell-1-based bone graft substitute for spinal fusion, also under exclusive license from UCLA. Nell-1 has demonstrated an ability to target bone formation with a high degree of safety, suggesting it to be an attractive treatment modality vs. other bone growth factors and implanted devices.

Sources: Bone Biologics Corporation, ORTHOWORLD Inc.

This article is a Member-only item of content. Members, please log in to read the complete post.
If you are not yet a Member, click here to learn more about purchasing ORTHOWORLD Membership.